PLAT and ischemic stroke: Currently, the only approved therapy by Food and Drug Administration (FDA) for ischemic stroke is recombinant tissue plasminogen activator (tPA) which shows narrow therapeutic index (NTI), potential side‐effect of hemorrhagic transformation, and is treated in very limited patients.2